BSE · 524322
Kabra Drugs Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹93 Cr with net profit ₹5 Cr — a 5.32% net margin, versus -169.57% the period before.
Shareholding
As of 2026-06-30
- Public100%
9,680 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
Not enough history.
52-week position
Where the current price sits in its yearly band
The band spans 5.71× from low to high.
Risk flags
Derived from disclosed data
- Reported zero revenue in 3 of the last 8 disclosed periods.
- 52-week range spans 5.71× (₹6.22 to ₹35.52) — an unusually wide band.
Peer comparison
Trading · ranked #290 of 677 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹4,05,623 Cr | 157.57 | 4.27 | 3.93% | 6.78% |
| Avenue Supermarts Limited | ₹2,46,353 Cr | 80.55 | 10.05 | 12.14% | 4.29% |
| Trent Ltd. | ₹1,48,393 Cr | 81.16 | 21.17 | 24.62% | 8.64% |
| FSN E-Commerce Ventures Ltd. | ₹95,539 Cr | 358.66 | 66.73 | 13.87% | 2.41% |
| Aegis Logistics Limited | ₹50,000 Cr | 39.96 | 8.25 | 14.83% | 13.95% |
| Vishal Mega Mart Limited | ₹48,736 Cr | 54.75 | 6.56 | 11.32% | 6.61% |
| Aditya Infotech Limited | ₹43,174 Cr | 90.47 | 22.97 | 19.61% | 9.77% |
| Premier Energies Limited | ₹41,182 Cr | 24.73 | 9.59 | 35.05% | 19.67% |
| Redington Limited | ₹32,080 Cr | 17.83 | 3.16 | 14.67% | 1.33% |
| Honasa Consumer Limited | ₹15,442 Cr | 61.2 | 10.96 | 14.16% | 9.75% |
| Kabra Drugs Ltd.(this company) | ₹44 Cr | 5.82 | 1.49 | 16.75% | 5.76% |
AI analysis
AI-generated · google/gemini-2.5-flashKabra Drugs Ltd. has a market capitalization of Rs 51 Cr. The company's PE ratio stands at 10.38, with an EPS of 2.09. Its book value is Rs 12.49, and it has a debt-to-equity ratio of 0.08.
Positives
- +The company has a low debt-to-equity ratio of 0.08.
- +Return on Capital Employed (ROCE) is 19.05%.
Negatives
- −Revenue in Mar 2024 was Rs 0 Cr, indicating no operational revenue for the period.
- −Promoter holding is 0% as of June 30, 2026.
- −Annual net profit was negative for five consecutive periods from Mar 2021 to Mar 2025, with a net profit of -1.0856 Cr in Mar 2025.
- −Profit margin is 5.36%, based on revenue of Rs 0.64 Cr.
Financial performance
The company reported revenue of Rs 0.64 Cr. Profitability for the most recent annual period was 5.36%. For the year ending March 2025, revenue was Rs 0.64 Cr, with a net profit of -1.0856 Cr. In the latest available quarterly results (Mar 2026), revenue was Rs 35.41 Cr and net profit was Rs 1.06 Cr.
Profitability & Returns
Kabra Drugs Ltd. recorded a Return on Equity (ROE) of 16.75% and a Return on Capital Employed (ROCE) of 19.05%. The overall profit margin for the company is 5.36%.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.08, indicating a low reliance on debt for financing its operations. No details on other specific assets or liabilities are provided.
Ownership & Pledges
As of June 30, 2026, public shareholding in Kabra Drugs Ltd. was 100%. Promoter holding is 0%, with no DII or FII participation. There are no reported promoter pledges. The total number of shareholders was 9680.
Data as of — price: 2026-09-23 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.